The use of abatacept or the antibody ipilimumab to block CTLA-4 is now a well-established anti-cancer medication, demonstrating the close relationship between IDO1 activation and autoimmune function as well as tumor formation (Belladonna et al., 2009). Here, IDO1 is linked to neoplasm.